Abstract Search

ea0089t6 | Trials In Progress | NANETS2022

ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

Hope Thomas , Mehr Samuel , Morris Michael , Li Daneng , Halperin, MD Daniel , Strosberg Jonathan , Soares Heloisa , Jacene Heather , Pavel Marianne , L. Kunz Pamela , Ferreira Denis , Li Joanne , Ma Kimberly , Rearden Jessica , Moran Susan , Singh Simron

Background: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly characterized by overexpression of somatostatin receptor subtype 2 (SSTR2), which can be targeted by radiopharmaceutical therapy (RPT) via radiolabeled somatostatin analogues (SSAs). RYZ101 (Ac-225 DOTATATE) is a first-in-class, highly potent alpha-emitting RPT being developed for the treatment of SSTR2+ solid tumors. Alpha-particles (such as emitted by Actinium-225) have a sho...

0 shares

Endocrine Abstracts

ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

BiosciAbstracts